VCNX Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Vaccinex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.95 |
| 52 Week High | US$13.44 |
| 52 Week Low | US$1.39 |
| Beta | 0.96 |
| 11 Month Change | 15.69% |
| 3 Month Change | -40.29% |
| 1 Year Change | -77.34% |
| 33 Year Change | -99.29% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.88% |
Recent News & Updates
Shareholder Returns
| VCNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.1% | -0.7% | -1.6% |
| 1Y | -77.3% | 19.8% | 30.8% |
Return vs Industry: VCNX underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: VCNX underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| VCNX volatility | |
|---|---|
| VCNX Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VCNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VCNX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 39 | Maurice Zauderer | www.vaccinex.com |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer.
Vaccinex, Inc. Fundamentals Summary
| VCNX fundamental statistics | |
|---|---|
| Market cap | US$7.67m |
| Earnings (TTM) | -US$17.76m |
| Revenue (TTM) | US$356.00k |
21.5x
P/S Ratio-0.4x
P/E RatioIs VCNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCNX income statement (TTM) | |
|---|---|
| Revenue | US$356.00k |
| Cost of Revenue | US$14.96m |
| Gross Profit | -US$14.60m |
| Other Expenses | US$3.15m |
| Earnings | -US$17.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.83 |
| Gross Margin | -4,101.97% |
| Net Profit Margin | -4,987.92% |
| Debt/Equity Ratio | -2.2% |
How did VCNX perform over the long term?
See historical performance and comparison